Novartis, an innovative medicines company, has announced plans to invest $23 billion over 5 years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patients will be made in the United States. Over the next 5 years, Novartis will: - Establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the U.S. - Build 4 new manufacturing facilities in soon-to-be-determined states, including 3 that will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging - Build 2 new radioligand therapy (RLT) manufacturing facilities in Florida and Texas - Expand 3 RLT manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA “As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the U.S. that supports our ability to find the next medical breakthroughs for patients,” said Vas Narasimhan, CEO of Novartis. “We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.” Over the next 5 years, the total investment in Novartis U.S. operations is expected to be nearly $50 billion, marking a clear demonstration of the company’s focus on the U.S. Congratulations to all involved! Read the full article here: https://lnkd.in/gte4dZiU
